Wealth Enhancement Advisory Services
ENTA icon

Wealth Enhancement Advisory Services’s Enanta Pharmaceuticals ENTA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Sell
13,315
-304
-2% -$4.09K ﹤0.01% 3623
2026
Q1 		$179K Buy
13,619
+2,898
+27% +$38.8K ﹤0.01% 3174
2025
Q4 		$146K Buy
10,721
+74
+0.7% +$940 ﹤0.01% 3354
2025
Q3 		$118K Sell
10,647
-464
-4% -$3.71K ﹤0.01% 3299
2025
Q2 		$87.7K Buy
+11,111
New +$66.8K ﹤0.01% 3155

Other funds holding ENTA

VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

Wealth Enhancement Advisory Services's ENTA Position: Q2 2026 in Review

Wealth Enhancement Advisory Services reduced its Enanta Pharmaceuticals (ENTA) stake by 2.2% in Q2 2026, selling an estimated $4.09K and leaving 13,315 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #3623.

Wealth Enhancement Advisory Services first reported a position in ENTA in Q2 2025 and has held it in 5 quarters since. 6 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Wealth Enhancement Advisory Services held 13,315 shares of Enanta Pharmaceuticals worth $182K as of Q2 2026.
  • Wealth Enhancement Advisory Services sold 304 Enanta Pharmaceuticals shares in Q2 2026, an estimated $4.09K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3623 holding.
  • Wealth Enhancement Advisory Services first reported a position in Enanta Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 6 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.